DefiniGEN Ltd

6 articles about DefiniGEN Ltd

• ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

  11/1/2018

  ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents.

• DefiniGEN strengthens Board with the appointment of Professor Sir John Savill

  9/11/2018

  DefiniGEN today announces the appointment of Professor Sir John Savill as a Non-Executive Director of the Board.

• DefiniGEN Ltd Raises £1.5 Million ($2.29 Million USD) In Follow-On Funding

  5/23/2016

• DefiniGEN Ltd Licences Lung Stem Cell Technology From University of Cambridge

  8/11/2015

• Horizon Discovery Group plc And DefiniGEN Ltd Announce Collaboration To Develop Gene-Engineered iPS-based Cell Lines

  6/10/2015

• DefiniGEN Ltd Joins European Bank For Induced Pluripotent Stem Cells (EBiSC) Consortium

  8/27/2014